Brii Biosciences
Breakthrough innovation & insight

Brii Biosciences Limited
腾盛博药生物科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2137)

INSIDE INFORMATION IN RELATION TO ARBITRATION PROCEEDINGS

This announcement is made by Brii Biosciences Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

On May 23, 2018, the Company and Brii Biosciences Offshore Limited (together, "**Brii**"), a subsidiary of the Company, entered into a Collaboration, Option, and License Agreement (the "**Collaboration Agreement**") with Vir Biotechnology, Inc. ("**Vir**"), which is a Delaware corporation with a place of business in San Francisco, California, pursuant to which each party may exercise options for an exclusive license to pursue the development and commercialization of certain products initially developed by the other party.

On June 12, 2020, Brii exercised its option for the elebsiran program, a small interfering RNA (siRNA) candidate that targets hepatitis B virus. On December 19, 2024, Brii and Vir entered into the Sixth Letter Agreement (the "**SLA**") to transfer drug product formulation manufacturing responsibility from Vir to Brii.

On April 16, 2026, Brii submitted a Demand for Arbitration to the United States-based Judicial Arbitration and Mediation Services, Inc. against Vir (the "**Arbitration**") for a contractual dispute arising from the Collaboration Agreement and the SLA. Brii alleges that Vir has breached the Collaboration Agreement and the SLA, and requests that Vir, among other forms of relief, (1) specifically perform its obligations under the Collaboration Agreement and the SLA to transfer the manufacturing of elebsiran to Brii or its contractor(s); and (2) pay Brii for all damages it suffered as a result of Vir's alleged breach of the Collaboration Agreement and the SLA to date, including without limitation Brii's lost profits due to Vir's alleged breach and the amounts Brii has invested to date in the collaboration in reliance upon Vir's express promises and good faith covenants. The Group will continue to seek legal advice and to take expedient actions to safeguard the best interest of the Group.

As of the date of this announcement, as the Arbitration is still in its initial stage, the Group is unable to accurately predict the final outcome of the Arbitration or evaluate the impact of the Arbitration on the Group's financial position. Should there be any further information regarding the Arbitration, the Company will make further announcements to inform the shareholders and the public as and when appropriate in accordance with relevant requirements.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Brii Biosciences Limited
Dr. Zhi Hong
Chairman

Hong Kong, April 16, 2026

As at the date of this announcement, the Board comprises Dr. Zhi Hong and Dr. Ankang Li as executive directors; Dr. Martin J Murphy Jr, Ms. Grace Hui Tang, Mr. Yiu Wa Alec Tsui, Mr. Gregg Huber Alton and Dr. Taiyin Yang as independent non-executive directors.